Exploring a Novel TGF-β Pathway Modulator
- GTX-11, an orally available TGF-β pathway modulator, has shown potent anti-fibrotic, anti-inflammatory, and vascular-protective effects across multiple preclinical models, including bleomycin-induced lung fibrosis, patient-derived fibroblasts, and precision-cut lung slices (PCLS)
- With an excellent preclinical safety and toxicology profile, GTX-11 effectively reduces SMAD2/3 activation, fibroblast-to-myofibroblast transition, and vascular dysfunction, positioning it as a promising therapeutic candidate
- Now in Phase I clinical trials, GTX-11 represents a promising new approach for treating fibrotic interstitial lung diseases (ILDs), offering potential advantages over existing therapies